HIV protease inhibitors: a review of molecular selectivity and toxicity

TLDR: From the chemical structures of HIV protease inhibitors and their possible off-target molecules, hints for optimizing the molecular selectivity of the inhibitors are obtained to provide help in the design of new compounds with enhanced bioavailability and reduced side effects.

Abstract: Highly active antiretroviral therapy (HAART) is recognized as the most effective treatment method for AIDS, and protease inhibitors play a very important role in HAART. However, poor bioavailability and unbearable toxicity are their common disadvantages. Thus, the development of safer and potentially promising protease inhibitors is eagerly needed. In this review, we introduced the chemical characteristics and associated side effects of HIV protease inhibitors, as well as the possible off-target mechanisms causing the side effects. From the chemical structures of HIV protease inhibitors and their possible off-target molecules, we could obtain hints for optimizing the molecular selectivity of the inhibitors, to provide help in the design of new compounds with enhanced bioavailability and reduced side effects.